Market Research Report
Epigenetics: Applications for Pharmaceuticals and Diagnostics (Methylation, Histone Modification and miRNA expression)
|Published by||Kalorama Information||Product code||248850|
|Published||Content info||160 Pages
|Epigenetics: Applications for Pharmaceuticals and Diagnostics (Methylation, Histone Modification and miRNA expression)|
|Published: August 10, 2012||Content info: 160 Pages||
Mabs" and molecular tests are among the growth industries of pharmaceuticals and diagnostics, but they may have competition long-term from an unexpected source. Epigenomics is a potential game-changer in the clinical therapeutics market and significant in testing as well. It refers to technologies involving changes in genetic material that find their origins in causes other than base pairs alterations in the DNA of the host. Examples of such changes include DNA methylation and histone acetylation, both of which have been known for many years to cause changes in gene expression. This report Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics describes the progress that has been made in our understanding of the basic science of epigenomics and considers the practical accomplishments being reported by the private sector.
Epigenomics constitutes a challenge to the long held paradigm of DNA base pair sequences as the prime determinant of the phenotype. Because of this profound intellectual shift, a vast new area of biological investigation is rapidly unfolding. This presents significant opportunities for understanding disease processes and developing the means of combating them.
Epigenomic Mechanisms Discussed in the report include:
The examination of many diseases in a completely new light means there exist a wealth of opportunities to develop new diagnostic and therapeutic approaches. At the same time it means that outdated concepts will have to be revised. This report looks at the science behind epigenomics and deals with opportunities for product development based on epigenetic technologies and the outlook for the future in this exciting area of pharmaceutical technologies.
In doing so, the report provides:
The report strives to predict the potential for epigenomics while reminding market-watchers of the challenges and possible limiting factors in this market. As the report states:
"In the examination of Google hits for “Epigenomics,” the phrases “exciting”, “state of the art”, “cutting edge”, “innovative”, “breakthrough” and other cliches are encountered over and over. These terms are frequently employed to cover up ideas, concepts and scientific discoveries that may NOT be cutting edge or state of the art and may be past their time, or may never have reached their time. For this reason the report will consider which of these technologies have value and may be ripe for exploitation."
The study of epigenomics today finds itself at a tuningpoint, with many unanswered questions and a proliferation of opportunities forproducts based on the constant flow of new research findings. This report is essential for pharmaceutical and diagnostic marketers looking to develop future business plans and determine opportunities in a promising field.
Table 1-1:The most common epigenetic alterations